Skip to main content
Sign In
 

Welcome to the Barbara Davis Center for Diabetes (BDC)


Barbara Davis Center for Diabetes

Mission:
Our mission is to provide state-of the-art care to children and adults with type 1 diabetes and to teach our patients how to prevent or delay complications. Our research is devoted to finding prevention, cure, and most effective treatment of diabetes and associated disorders.
Marian Rewers, MD, PhD
Executive Director 

The Barbara Davis Center for Diabetes (BDC) specializes in type 1 diabetes research and care for children and adults. It is one of the largest diabetes institutes in the world. The Center is part of the University of Colorado School of Medicine and has its dedicated building on the Anschutz Medical Campus  (map) in Aurora, Colorado. The Center was funded by Marvin Davis, in 1978, and is generously supported by the Children’s Diabetes Foundation (CDF)​.
Clinicians, clinical researchers, and basic biomedical scientists work at the BDC to find the most effective treatment, prevention, and cure for type 1 diabetes. The Center provides state-of-the-art diabetes care to 3600 children and 2400 adults with diabetes from the Rocky Mountain Region as well as receiving national and international referrals. We also provide inpatient care to patients who are seen at the Children’s Hospital Colorado with any type of diabetes.
The Center’s faculty teach the medical, physician assistant, nursing, and dental students on campus. Residents and endocrinology fellows train at the Center on elective rotations. Basic science faculty members provide mentorship to pre-doctoral students and post-doctoral fellows from around the world.




Childhood Diabetes Prevention Day: 
General Population Screening for T1D
February 9th, 2018
Shore Family Auditorium, Nighthorse Campbell Native Health Building, AMC

​Type 1 diabetes (T1D) affects 1.3 million people in the U.S. Their expected lifetime medical expenses and income loss due to diabetes add to $643 billion, in 2016 dollars. The incidence continues to increase 3-5% annually. The JDRF, the American Diabetes Association, and the Endocrine Society have recognized that T1D should be diagnosed when a child develops multiple islet autoantibodies (stage 1) irreversibly leading to dysglycemia (stage 2) and symptomatic hyperglycemia (stage 3 T1D). Major ongoing studies are testing interventions at stages 1 and 2, to prevent or delay life-long insulin dependence. Mass-screening for stage 1 T1D provides access to the prevention trials and prevents life-threatening diabetic ketoacidosis at diagnosis. The objectives of this symposium are: 1) to review findings from the ongoing screening programs; 2) to identify barriers to a wide-spread implementation, and 3) to build consensus how to address the barriers and what evidence is needed for public health acceptance of screening for T1D.

Schedule of symposium.​